We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$713M
Cap. Flow
+$1.03B
Cap. Flow %
77.19%
Top 10 Hldgs %
46.07%
Holding
196
New
82
Increased
39
Reduced
17
Closed
45

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$20M
2
XLRN
Acceleron Pharma
XLRN
+$18.6M
3
TARA icon
Protara Therapeutics
TARA
+$12.9M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$12M
5
VSTM icon
Verastem
VSTM
+$11M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$5.72M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.63M
3
TGTX icon
TG Therapeutics
TGTX
+$3.51M
4
KALA icon
KALA BIO
KALA
+$3.39M
5
ARQL
Arqule Inc
ARQL
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 19.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
126
Karyopharm Therapeutics
KPTI
$44.6M
$700K 0.05%
+2,428
New +$670K
AVDL
127
DELISTED
Avadel Pharmaceuticals
AVDL
$652K 0.05%
+82,143
New +$631K
RARE icon
128
Ultragenyx Pharmaceutical
RARE
$2.46B
$633K 0.05%
14,252
-35,748
-71% -$1.86M
NERV icon
129
Minerva Neurosciences
NERV
$185M
$623K 0.05%
12,938
+438
+4% +$26.4K
OTIC
130
CALL
DELISTED
Otonomy, Inc.
OTIC
$591K 0.04%
+300,000
New +$925K
VKTX icon
131
Viking Therapeutics
VKTX
$3.8B
$590K 0.04%
126,159
– –
PFNX
132
DELISTED
Pfenex Inc.
PFNX
$566K 0.04%
+64,211
New +$706K
KOD icon
133
PUT
Kodiak Sciences
KOD
$2.49B
$563K 0.04%
+11,800
New +$708K
PGNX
134
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$497K 0.04%
130,845
– –
PBYI icon
135
Puma Biotechnology
PBYI
$391M
$463K 0.03%
54,901
-256,352
-82% -$2.49M
SIOX
136
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$461K 0.03%
188,884
– –
BXRX
137
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$434K 0.03%
+125
New +$1.18M
MNK
138
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$385K 0.03%
194,322
-317,678
-62% -$1.2M
CMRX
139
DELISTED
Chimerix, Inc.
CMRX
$300K 0.02%
208,258
+35,338
+20% +$61.8K
BLUE
140
DELISTED
bluebird bio
BLUE
$299K 0.02%
+502
New +$489K
CLLS
141
Cellectis
CLLS
$277M
$285K 0.02%
+30,928
New +$461K
DRNA
142
CALL
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$285K 0.02%
15,500
– –
TVRD
143
CALL
Tvardi Therapeutics
TVRD
$19M
$259K 0.02%
544
+52
+11% +$28.3K
BIIB icon
144
Biogen
BIIB
$29.8B
$252K 0.02%
+795
New +$241K
ARWR icon
145
PUT
Arrowhead Research
ARWR
$12.1B
$207K 0.02%
7,200
-92,800
-93% -$3.74M
DBVT
146
PUT
DBV Technologies
DBVT
$804M
$207K 0.02%
+5,280
New +$473K
OBSV
147
DELISTED
ObsEva SA Ordinary Shares
OBSV
$199K 0.02%
82,573
– –
AMRN
148
CALL
Amarin Corp
AMRN
$297M
$159K 0.01%
1,985
-8,890
-82% -$2.95M
CSCI
149
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$60K ﹤0.01%
1,174
– –
MITO
150
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$47K ﹤0.01%
37,597
– –
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Ikarian Capital held 196 positions worth $1.33B, up 115% from $617M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ikarian Capital deployed $1.03B of net new capital in Q1 2020, opening 82 new positions and adding to 39 existing holdings. Its largest new stake was Zogenix, Inc.: 549,459 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 16% a quarter earlier.

On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $4.63M trimmed.

  • Ikarian Capital's largest Q1 2020 buy was Zogenix, Inc.: 549,459 shares worth $13.6M.
  • Ikarian Capital added most to Protara Therapeutics in Q1 2020, an estimated $12.9M increase.
  • Ikarian Capital's biggest Q1 2020 reduction was Aurinia Pharmaceuticals, cutting an estimated $4.63M.
  • Ikarian Capital fully exited Aptose Biosciences, Inc. in Q1 2020, selling an estimated $5.72M.
  • Ikarian Capital's ten largest holdings make up 46% of its $1.33B portfolio in Q1 2020.
  • Ikarian Capital opened 82 new positions and closed 45 in Q1 2020.
  • Ikarian Capital's portfolio value rose 115% quarter-over-quarter to $1.33B.

Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.